Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1810214rdf:typepubmed:Citationlld:pubmed
pubmed-article:1810214lifeskim:mentionsumls-concept:C0021755lld:lifeskim
pubmed-article:1810214lifeskim:mentionsumls-concept:C0021467lld:lifeskim
pubmed-article:1810214lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:1810214lifeskim:mentionsumls-concept:C0021469lld:lifeskim
pubmed-article:1810214lifeskim:mentionsumls-concept:C2587213lld:lifeskim
pubmed-article:1810214lifeskim:mentionsumls-concept:C1533691lld:lifeskim
pubmed-article:1810214lifeskim:mentionsumls-concept:C0074810lld:lifeskim
pubmed-article:1810214pubmed:issue3lld:pubmed
pubmed-article:1810214pubmed:dateCreated1992-5-27lld:pubmed
pubmed-article:1810214pubmed:abstractTextSoluble immune response suppressor (SIRS), a nonspecific inhibitor of cellular and humoral immune responses and cellular proliferation, reversed IL-1-induced inhibition of autologous rosette formation by thymocytes. In addition, SIRS prevented the IL-1-induced increase in resistance of thymocytes to the lytic action of hydrocortisone. Kinetic experiments showed that the action of SIRS on thymocytes was rapid (less than 15 minutes), although a longer time was required to exert protective effects on thymocytes. SIRS also inhibited the stimulation of thymocyte proliferation induced by Con A and IL-1 a costimulatory assay of IL-1 activity. Moreover, SIRS inhibited the IL-1-stimulated expression of complement receptors on neonatal B cells. The inhibitory effects of SIRS were selectively directed towards IL-1, since SIRS did not interfere with induction of LAK cells by IL-2, and did not reverse inhibition of autologous rosette formation induced by factors other than IL-1, such as IL-4, a proline rich polypeptide and lactoferrin. The results presented in this report demonstrate that SIRS may be a selective inhibitor of IL-1 activity with respect to T and B cells, rendering them unresponsive to IL-1 activation and/or maturation signals.lld:pubmed
pubmed-article:1810214pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1810214pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1810214pubmed:languageenglld:pubmed
pubmed-article:1810214pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1810214pubmed:citationSubsetIMlld:pubmed
pubmed-article:1810214pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1810214pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1810214pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1810214pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1810214pubmed:statusMEDLINElld:pubmed
pubmed-article:1810214pubmed:issn0004-069Xlld:pubmed
pubmed-article:1810214pubmed:authorpubmed-author:PierceC WCWlld:pubmed
pubmed-article:1810214pubmed:authorpubmed-author:SchnaperH WHWlld:pubmed
pubmed-article:1810214pubmed:authorpubmed-author:WieczorekZZlld:pubmed
pubmed-article:1810214pubmed:authorpubmed-author:ZimeckiMMlld:pubmed
pubmed-article:1810214pubmed:authorpubmed-author:KappJ AJAlld:pubmed
pubmed-article:1810214pubmed:authorpubmed-author:WebbD RDRlld:pubmed
pubmed-article:1810214pubmed:issnTypePrintlld:pubmed
pubmed-article:1810214pubmed:volume39lld:pubmed
pubmed-article:1810214pubmed:ownerNLMlld:pubmed
pubmed-article:1810214pubmed:authorsCompleteYlld:pubmed
pubmed-article:1810214pubmed:pagination213-26lld:pubmed
pubmed-article:1810214pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:1810214pubmed:meshHeadingpubmed-meshheading:1810214-...lld:pubmed
pubmed-article:1810214pubmed:meshHeadingpubmed-meshheading:1810214-...lld:pubmed
pubmed-article:1810214pubmed:meshHeadingpubmed-meshheading:1810214-...lld:pubmed
pubmed-article:1810214pubmed:meshHeadingpubmed-meshheading:1810214-...lld:pubmed
pubmed-article:1810214pubmed:meshHeadingpubmed-meshheading:1810214-...lld:pubmed
pubmed-article:1810214pubmed:meshHeadingpubmed-meshheading:1810214-...lld:pubmed
pubmed-article:1810214pubmed:meshHeadingpubmed-meshheading:1810214-...lld:pubmed
pubmed-article:1810214pubmed:meshHeadingpubmed-meshheading:1810214-...lld:pubmed
pubmed-article:1810214pubmed:meshHeadingpubmed-meshheading:1810214-...lld:pubmed
pubmed-article:1810214pubmed:meshHeadingpubmed-meshheading:1810214-...lld:pubmed
pubmed-article:1810214pubmed:meshHeadingpubmed-meshheading:1810214-...lld:pubmed
pubmed-article:1810214pubmed:meshHeadingpubmed-meshheading:1810214-...lld:pubmed
pubmed-article:1810214pubmed:meshHeadingpubmed-meshheading:1810214-...lld:pubmed
pubmed-article:1810214pubmed:year1991lld:pubmed
pubmed-article:1810214pubmed:articleTitleControl of interleukin 1 (IL-1) activity. I. Inhibition of IL-1 activity by soluble immune response suppressor (SIRS) in vitro.lld:pubmed
pubmed-article:1810214pubmed:affiliationDepartment of Experimental Therapy, Polish Academy of Sciences, Wroc?aw.lld:pubmed
pubmed-article:1810214pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1810214pubmed:publicationTypeIn Vitrolld:pubmed
pubmed-article:1810214pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed